Joint venture aims to streamline handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation.
Clario, a healthcare research technology company, and CellCarta, an organization focused on integrated sample management and specialized laboratory services, have announced a strategic partnership aimed to improve clinical trial sample handling. Additionally, the companies hope to streamline the handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation across multiple therapeutic areas, including oncology, hepatology (e.g., NASH), and gastroenterology (e.g., UC and Crohn's).
"This collaboration brings together Clario's cutting-edge scientific expertise and unrivaled clinical trial endpoint solutions with CellCarta's unparalleled sample processing and management expertise," noted Joyce Suhy, PhD, EVP, medical imaging, and specialty solutions, Clario. "This partnership advances Clario's ability to support histopathology studies, providing our customers with full visibility for biopsy sample logistics and significantly accelerates delivery of centralized assessments for eligibility and efficacy endpoints."
Reference: Clario teams up with CellCarta to transform clinical trial sample management for histopathology studies. PR Newswire. September 26, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/clario-teams-up-with-cellcarta-to-transform-clinical-trial-sample-management-for-histopathology-studies-301937860.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.